pentapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
For nanoparticles dispersed in a medium of different composition, the interfacial layer — formed by ions and molecules from the medium that are within a few atomic diameters of the surface of each particle — can mask or change its chemical and physical properties. Indeed, that layer can be considered an integral part of each nanoparticle.
With the recent advances of noninvasive imaging, living liver donors usually have to undergo imaging examinations for liver anatomy to decide if the anatomy is feasible for donation. The evaluation is usually performed by multidetector row computed tomography (MDCT) and magnetic resonance imaging (MRI). MDCT is good in vascular anatomy and volumetry. MRI is used for biliary tree anatomy. Donors with very unusual vascular anatomy, which makes them unsuitable for donation, could be screened out to avoid unnecessary operations.
mass spectrometry (MS) An analytical technique that measures the mass-to-charge ratio of ions in a chemical sample by bombarding the sample with electrons to the point of ionization and then separating the charged fragments by subjecting them to an electric or magnetic field, typically in order to determine the elemental or isotopic signatures of an unknown substance, the masses of its constituent particles, and/or the identities or structures of the molecules within it. The results are presented as a mass spectrum, a plot of the intensity of ion signals as a function of the mass-to-charge ratio.
Sources: en.wikipedia.org
== History == Famotidine was developed by Yamanouchi Pharmaceutical Co. It was licensed in the mid-1980s by Merck & Co. and is marketed by a joint venture between Merck and Johnson & Johnson. The imidazole ring of cimetidine was replaced with a 2-guanidinothiazole ring. Famotidine proved to be nine times more potent than ranitidine, and thirty-two times more potent than cimetidine. It was first marketed in 1981. Pepcid RPD orally disintegrating tablets were released in 1999. Generic preparations became available in 2001, e.g. Fluxid (Schwarz) or Quamatel (Gedeon Richter Ltd.). In the United States and Canada, a product called Pepcid Complete, which combines famotidine with an antacid in a chewable tablet to relieve the symptoms of excess stomach acid quickly, is available. In the UK, this product was known as PepcidTwo until its discontinuation in April 2015. Famotidine has poor bioavailibility (50%) due to its low solubility in the high pH of the intestines. Researchers are developing formulations that use gastroretentive drug delivery systems such as floating tablets to increase bioavailability by promoting local delivery (directly into the stomach wall) of these drugs to receptors in the parietal cell membrane.
=== Main centre leaders === Mayor of Auckland – Wayne Brown Mayor of Tauranga – Mahé Drysdale Mayor of Hamilton – Paula Southgate, then Tim Macindoe from 19 October Mayor of Wellington – Tory Whanau, then Andrew Little from 17 October Mayor of Christchurch – Phil Mauger Mayor of Dunedin – Jules Radich, then Sophie Barker from 17 October
== A == Acetylcholine A neurotransmitter involved in muscle activation, attention, arousal, and memory. It acts at both nicotinic and muscarinic receptors throughout the central and peripheral nervous systems. Achromatopsia Loss of color vision as a result of damage to extrastriate visual cortex. Action Potential A rapid electrical signal that travels down the axon of a neuron. Activation The time-dependent opening of ion channels in response to a stimulus, typically membrane depolarization. Adaptation The phenomenon of sensory receptor adjustment to different levels of stimulation; critical for allowing sensory systems to operate over a wide dynamic range. Adenylyl cyclase Membrane-bound enzyme that can be activated by G-proteins to catalyze the synthesis of cyclic AMP from ATP. Adrenal cortex The outer region of the adrenal gland, responsible for producing steroid hormones such as cortisol and aldosterone, which regulate metabolism and stress responses. Adrenal medulla The central part of the adrenal gland that, under visceral motor stimulation, secretes epinephrine and norepinephrine into the bloodstream. Adrenaline See epinephrine. Afferent nerve fiber An axon that conducts action potentials from the periphery toward the central nervous system. Agnosia The inability to name objects, typically resulting from brain damage in the occipital or temporal lobes. Agonist A chemical that binds to and activates a receptor, mimicking the action of a natural neurotransmitter.
In the Paris Agreements of 23 October 1954, France offered to establish an independent "Saarland", under the auspices of the Western European Union (WEU), but on 23 October 1955 in the Saar Statute referendum the Saar electorate rejected this plan by 67.7% to 32.3% (out of a 96.5% turnout: 423,434 against, 201,975 for) despite the public support of Federal German Chancellor Konrad Adenauer for the plan. The rejection of the plan by the Saarlanders was interpreted as support for the Saar to join the Federal Republic of Germany. On 27 October 1956, the Saar Treaty established that Saarland should be allowed to join Germany, as provided by the German constitution. Saarland became part of Germany effective 1 January 1957. The Franco-Saarlander currency union ended on 6 July 1959, when the Deutsche Mark was introduced as legal tender in the Saarland.
Sources: en.wikipedia.org
== Upper mevalonate pathway == The mevalonate pathway of eukaryotes, archaea, and eubacteria all begin the same way. The sole carbon feed stock of the pathway is acetyl-CoA. The first step condenses two acetyl-CoA molecules to yield acetoacetyl-CoA. This is followed by a second condensation to form HMG-CoA (3-hydroxy-3- methyl-glutaryl-CoA). Reduction of HMG-CoA yields (R)-mevalonate. These first 3 enzymatic steps are called the upper mevalonate pathway.
== Image and legacy == Noriega's authoritarian rule of Panama has been described as a dictatorship, while Noriega himself has been referred to as a "strongman". A 2017 obituary from the BBC stated that Noriega "was an opportunist who used his close relationship with the United States to boost his own power in Panama and to cover up the illegal activities for which he was eventually convicted". A 2010 article in The Guardian referred to him as the best known dictator of his time, and as "Panama's answer to Libyan leader Colonel Muammar Gaddafi". Dinges writes that though Noriega's regime saw a number of murders and crimes, they were similar in scale to those that occurred at the same time under the authoritarian governments of Guatemala, Chile, Argentina, and El Salvador; these governments never saw the level of condemnation from the U.S. that Noriega's did. Others likened him to former Iraqi president Saddam Hussein. Like Saddam, Noriega enjoyed brief U.S. support until he turned into an enemy. After Noriega's death, an article in The Atlantic compared him to Castro and Augusto Pinochet, stating that while Castro had been the nemesis of the U.S., and Pinochet had been its ally, Noriega had managed to be both. It called Noriega the archetype of U.S. intervention in Latin America: "The lawless, vicious leader whom the U.S. cultivated and propped up despite clear and serious flaws." The author stated that although Panama was a freer democracy after Noriega's removal, it was still plagued by corruption and drug trafficking, while Daniel Ortega, whom the U.S.
== History == Golodirsen was developed by collaborative research led by Prof. Steve Wilton and Prof. Sue Fletcher in the Perron Institute and licensed to Sarepta Therapeutics by the University of Western Australia. In the clinical trial of golodirsen, dystrophin levels increased, on average, from 0.10% of normal at baseline to 1.02% of normal after 48 weeks of treatment with the drug or longer. The change was a surrogate endpoint and the trial did not establish clinical benefit of the drug, including changes to the subject's motor function. The pharmacological assessment of golodirsen did not include special population groups, e.g., pregnant and lactating women, the elderly, and people with concurrent disease states. As DMD predominantly affects male children and young adults, and golodirsen is indicated for the treatment of children, but primarily not for adult women, the elderly, and people with comorbidity, it was not evaluated on them. The US Food and Drug Administration (FDA) approved golodirsen in December 2019, under the accelerated approval pathway. The application for golodirsen was granted fast track, priority review, and orphan drug designations, and a rare pediatric disease priority review voucher.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
不是。它属于人工合成的五肽，设计上模拟胃饥饿素受体的部分作用，但不存在于人体天然激素谱中。